Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

References

• Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202–19.
   PubMed Web of Science ®Google Scholar
• Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dyonisos nutrition and liver study. Hepatology. 2005;42:44–52.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, . Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, . Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–40.
   PubMed Web of Science ®Google Scholar
• Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu. 1989;24 Pt 1:275–302.
   PubMedGoogle Scholar
• Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on non-alcoholic fatty liver disease (NAFLD): systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–402.
   PubMed Web of Science ®Google Scholar
• Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, . Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2008;134:85–94.
   PubMed Web of Science ®Google Scholar
• Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
   PubMed Web of Science ®Google Scholar
• Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005; 112:2130–7.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147:573–7.
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, . Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Biochem. 2003;36:2–7.
   PubMed Web of Science ®Google Scholar
• Leeflang MG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44:837–45.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, . Decreased survival of subjects with elevated liver function tests during a 28 year follow up. Hepatology. 2010;51:595–602.
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.
   PubMed Web of Science ®Google Scholar
• Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatology. 2008;49:608–12.
   PubMed Web of Science ®Google Scholar
• Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, . Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–71.
   PubMed Web of Science ®Google Scholar
• Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, . Prognosis of patients with a diagnosis of fatty liver—a registry-based cohort study. Hepatogastroenterology. 2003;50:2101–4.
   PubMedGoogle Scholar
• Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403–11.
   PubMed Web of Science ®Google Scholar
• Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995;142:699–708.
   PubMed Web of Science ®Google Scholar
• Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia. 2003;46:359–64.
   PubMed Web of Science ®Google Scholar
• Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, . Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2004;53:2855–60.
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27: 1427–32.
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, Dekker JM, Nijpels G, Heine RJ, Diamant M. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study. Diabetes Care. 2005;28:2812.
   Google Scholar
• Hozawa A, Okamura T, Kadowaki T, Murakami Y, Nakamura K, Hayakawa T, . gamma-Glutamyltransferase predicts cardiovascular death among Japanese women. Atherosclerosis. 2007;194:498–504.
   Google Scholar
• Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913–8.
   PubMed Web of Science ®Google Scholar
• Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476–81.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol. 2003;13:15–21.
   Web of Science ®Google Scholar
• Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940–4.
   PubMed Web of Science ®Google Scholar
• Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, . Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity. 2007;15:1841–50.
   Google Scholar
• André P, Balkau B, Born C, Royer B, Wilpart E, Charles MA, . Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. Diabetes Metab. 2005;31:542–50.
   PubMed Web of Science ®Google Scholar
• Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev. 2009; 25:64–9.
   PubMed Web of Science ®Google Scholar
• Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ. 2006;33:22.
   Google Scholar
• Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JC, . Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care. 2007;30:2566–8.
   Google Scholar
• Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation Into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.
   PubMed Web of Science ®Google Scholar
• Jiamjarasrangsi W, Sangwatanaroj W, Lohsoonthorn V, Lertmaharit S. Increased alanine aminotransferase level and future risk of type 2 diabetes and impaired fasting glucose among the employees in a university hospital in Thailand. Diabetes Metab. 2008;34:283–9.
   Google Scholar
• Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, . Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–92.
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, . Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623–32.
   PubMed Web of Science ®Google Scholar
• Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, . Liver enzymes, the metabolic syndrome, and incident diabetes: The Mexico City diabetes study. Diabetes Care. 2005;28:1757–62.
   PubMed Web of Science ®Google Scholar
• Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, . High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–95.
   PubMed Web of Science ®Google Scholar
• Sato KK, Hayashi T, Nakamura Y, Harita N, Yoneda T, Endo G, . Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2008;31:1230–6.
   PubMedGoogle Scholar
• Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma glutamyltransferase and incident diabetes: The British Women's Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, . Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–21.
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, . Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391–6.
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, . Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–33.
   PubMed Web of Science ®Google Scholar
• Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007;27:2729–35.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, . Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541–6.
   PubMed Web of Science ®Google Scholar
• Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J, . Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J. 2006;27:2170–6.
   PubMed Web of Science ®Google Scholar
• Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, . Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009; 7:234–8.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, . Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–84.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. Serum γ-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med. 2005;258:527–35.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Doring A, Schneider A, Lowel H. Serum γ-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis. 2006;189:297–302.
   PubMed Web of Science ®Google Scholar
• Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935–44.
   PubMed Web of Science ®Google Scholar
• Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol. 2009;104:1715–22.
   PubMed Web of Science ®Google Scholar
• Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatology. 2008;49:600–7.
   PubMed Web of Science ®Google Scholar
• Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, . Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105:1567–73.
   PubMed Web of Science ®Google Scholar
• Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, . Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004; 53:750–5.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, . Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–9.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017–44.
   PubMed Web of Science ®Google Scholar
• Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, . Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004;50:1344–55.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, . LIDO Study Group. Sampling variability of liver biopsy in non-alcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.
   PubMed Web of Science ®Google Scholar
• Arubn J, Jhala N, Lazenby AJ, Clements R, Abrams GA. Influence of liver biopsy heterogeneity and diagnosis on non-alcoholic steatohepatitis in subjects undergoing gastric bypass. Obesity Surg. 2007;17:155–61.
   Google Scholar
• Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, . Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792–8.
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology. 1999;30:1356–62.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, . Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.
   PubMed Web of Science ®Google Scholar
• Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, . Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2005;40:1469–77.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2005;28:1222–4.
   PubMed Web of Science ®Google Scholar
• Kelleher T, MacFarlane C, de Ledinghen V, Beaugrand M, Foucher J, Castera L, . Risk factors and hepatic elastography (FibroScan) in the prediction of hepatic fibrosis in non-alcoholic steatohepatitis. Gastroenterology. 2006;130:A736.
   Google Scholar
• Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, . Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40:371–8.
   PubMedGoogle Scholar
• Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, . Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48:442–8.
   PubMed Web of Science ®Google Scholar
• Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, . Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–62.
   PubMed Web of Science ®Google Scholar
• Obara N, Ueno Y, Fukushima K, Nakagome Y, Kakazu E, Kimura O, . Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases. J Gastroenterol. 2008;43:720–8.
   PubMed Web of Science ®Google Scholar
• Chang PE, Lui HF, Chau YP, Lim KH, Yap WM, Tan CK, . Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther. 2008;28:51–61.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F. Diagnostic value of biochemical markers (Nash Test) for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2006;6:34.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology. 2006;44:27–33.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Jarrar M, Nugent C, Randahawa M, Afendy M, Stepanova M. A novel diagnostic biomarker panel for obesity-related non-alcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430–7.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50:1072–8.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, . Solubile forms of extracellular cytokeratin 18 may differentiate simple steatosis from non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13:837–44.
   PubMed Web of Science ®Google Scholar
• Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, . Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6:1249–54.
   PubMed Web of Science ®Google Scholar
• Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, . The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24:564–8.
   PubMed Web of Science ®Google Scholar
• Zein CO, Edmison JM, Schluchter M, Feldstein AE, Zein NN, McCullough AJ. A NASH predictive index (NPI) for use in patients with non-alcoholic fatty liver disease. Hepatology. 2007;46(S1):747A.
   Google Scholar
• Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, . A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916–23.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, . Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2006;6:6.
   PubMed Web of Science ®Google Scholar
• Adams LA, Gorge J, Rossi E, van der Poorten D, Kench JG, DeBoer B, . Non-invasive prediction of liver fibrosis in nonalcoholic fatty liver disease. Hepatology. 2008;48:520A.
   Google Scholar
• Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.
   PubMed Web of Science ®Google Scholar
• Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, . Noninvasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455–60.
   PubMed Web of Science ®Google Scholar
• Tabesh A, Duan Z, Kleiner DE, Wright EC, Loomba R, Liang TJ, . Serum caspase-3 generated cytokeratin 18 fragments (CK-18) as a marker for non-alcoholic steatohepatitis (NASH) and response to therapy. Hepatology. 2008;48(S1):803A.
   Google Scholar
• Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, . Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165–73.
   PubMed Web of Science ®Google Scholar
• Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, . Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009;136:160–7.
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, . Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008;103:1682–8.
   PubMed Web of Science ®Google Scholar
• Qureshi K, Clements RH, Abrams GA. The utility of the ‘NAFLD fibrosis score’ in morbidly obese subjects with NAFLD. Obes Surg. 2008;18:264–70.
   Google Scholar
• Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.
   PubMed Web of Science ®Google Scholar
• Guturu P, Steffer K, Petersen JR, Snyder N. A risk index for the estimation of fibrosis in non alcoholic fatty liver disease (NAFLD): comparison with the Mayo Score and the AST platelet ratio index (APRI). Hepatology. 2008;48(4S):522A.
   Google Scholar
• Musso G, Gambino R, Durazzo M, Cassader M. Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology. 2010;51:715–7.
   PubMed Web of Science ®Google Scholar
• Crisan D, Grigorescu MD, Grigorescu D, Feier D, Saplacan M, Serban A. Cytokeratin 18 fragments levels and dehydroepiandrosterone: valuable markers of nonalcoholic fatty liver disease. 2009 EASL Special Conference on NAFLD/NASH and related metabolic disorders abs 39 Page 122.
   Google Scholar
• Parker R, Collins P, McCune A. Can clinical scoring systems replace liver biopsy in non-alcoholic fatty liver disease? 2009 EASL Special Conference on NAFLD/NASH and related metabolic disorders abs 101 Page 189.
   Google Scholar
• Ruffillo GE, Fassio E, Alvarez E, Landeira G, Longo CG, Domnguez N, . Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009;50(S4):782A.
   Google Scholar
• Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P, . Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010;10:67.
   PubMedGoogle Scholar
• Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, . A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2010 Sep 15. [Epub ahead of print]. PMID: 20842510
   Google Scholar
• Fuji H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Application of non-invasive laboratory tests for the assessment of fibrosis staging in Japanese patients with NAFLD. 2009 EASL Special Conference on NAFLD/NASH and related metabolic disorders abs 49 Page 134.
   Google Scholar
• Munteanu M, Poynard T, Charlotte F, Jacqueminet S, Messous D, Podevin P, . Utility of a combination of non-invasive biomarkers (Fibromax) in assessing the efficacy of rosiglitazone in a one year randomized, double-blind trial in non alcoholic steatohepatitis. Gastroenterology. 2007;132(4 S1):S283.
   Google Scholar
• Hollebecque A, Monteanu M, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, . Diagnostic value of liver injury biomarkers, fibrotest(FT), steatotest(ST), NASHtest(NT) in patients without advanced disease undergoing bariatric surgery. Hepatology. 2009;50(4 Suppl):793A.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32 Suppl 1:S13–61.
   PubMed Web of Science ®Google Scholar
• Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399–402.
   PubMedGoogle Scholar
• Su CC, Wang K, Hsia TL, Chen CS, Tung TH. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.
   Google Scholar
• Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, . Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1215–22.
   PubMed Web of Science ®Google Scholar
• Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, . Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 2009;29:525–9.
   Google Scholar
• Shiga T, Moriyoshi Y, Nagahara H, Shiratori K. Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. J Gastroenterol. 2009;44:757–64.
   Google Scholar
• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, . A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–307.
   PubMed Web of Science ®Google Scholar
• Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, . Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93–111.
   PubMed Web of Science ®Google Scholar
• Foucher J, Castera L, Bernard PH, Carvalho F, Allaix D, Merrouche W, . Pitfalls of liver stiffness measurement: A 5-year prospective study of 13 369 examinations. Hepatology. 2010;51:828–35.
   Google Scholar
• de Ledinghen V, Fournier C, Foucher J, Miette V, Vergniol J, Rigalleau V, . New Fibroscan probe for obese patients. A pilot study of feasibility and performances in patients with BMI>30 kg/m2. J Hepatol. 2009;50(Suppl 1):S359.
   Google Scholar
• Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371–9.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, . Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549–57.
   PubMed Web of Science ®Google Scholar
• Ngo Y, Munteanu M, Dessous D, Charlotte F, Imbert-Bismut F, Thabut D, . A prospective analysis of the prognostic value of biomarkers (FibroTest) inpatients with chronic hepatitis C. Clin Chem. 2006;52:1887–96.
   PubMed Web of Science ®Google Scholar
• Pimentel SK, Strobel R, Gonçalves CG, Sakamoto DG, Ivano FH, Coelho JCU. Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arq Gastroenterol. 2010;47:170–3.
   Google Scholar